glp-1 agonists reduce inflammation Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits Frontiers | GLP-1 Receptor Agonists:

Long-term safety data still pending

Liraglutide has shown significant weight loss compared with placebo with the majority of participants achieving more than 5% total body weight loss during the follow up period and 33% (vs 10%) achieving 10% total body weight loss or greater

Future research should aim to unravel the precise molecular mechanisms underlying these weight-independent benefits, enabling the development of new therapies that harness these anti-inflammatory pathways and potentially bypass the limitations of current interventions

Participants receiving Ozempic lost an average of 3.6 kg (7.9 lbs) for the 0.5 mg dose and 4.9 kg (10.8 lbs) for the 1 mg dose after 104 weeks

There are clinical trials evaluating if these GLP-1 and multi-agonists can address neurodegeneration, addiction, inflammation, and beyond

GLP-1 agonists mimic the GLP-1 hormone, helping regulate insulin, glucose, and appetite